Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3594MR)

This product GTTS-WQ3594MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3594MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5896MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ4400MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ15457MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ8197MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ14657MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ6182MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ10992MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ10981MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW